$2975 | SAVE $525 | Single User
$5950 | SAVE $1,050 | Site License
$8925 | SAVE $1,575 | Enterprise License

Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Pipeline Review, H2 2016
[Published by Global Markets Direct]

Published by Global Markets Direct: 16 Nov 2016 | 32495 | In Stock
Related Topics: Protein

Introduction

Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Pipeline Review, H2 2016’, provides in depth analysis on Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1)

- The report reviews Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

- The report assesses Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
for Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Pipeline Review, H2 2016 [Published by Global Markets Direct]

  • Table of Contents

    Table of Contents 2

    List of Tables 7

    List of Figures 8

    Introduction 9

    Global Markets Direct Report Coverage 9

    Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) Overview 10

    Therapeutics Development 11

    Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Products under Development by Stage of Development 11

    Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Products under Development by Therapy Area 12

    Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Products under Development by Indication 13

    Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Pipeline Products Glance 16

    Late Stage Products 16

    Early Stage Products 17

    Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Products under Development by Companies 18

    Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Products under Development by Universities/Institutes 30

    Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Therapeutics Assessment 32

    Assessment by Monotherapy/Combination Products 32

    Assessment by Mechanism of Action 33

    Assessment by Route of Administration 35

    Assessment by Molecule Type 37

    Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Companies Involved in Therapeutics Development 39

    AB Science SA 39

    Advenchen Laboratories, LLC 41

    Amgen Inc. 42

    ArQule, Inc. 43

    Ascendis Pharma A/S 44

    Astellas Pharma Inc. 45

    AstraZeneca Plc 46

    AVEO Pharmaceuticals, Inc. 47

    Bayer AG 48

    Boehringer Ingelheim GmbH 49

    Bristol-Myers Squibb Company 50

    CASI Pharmaceuticals Inc. 51

    Celon Pharma Sp. z o.o. 52

    Debiopharm International SA 53

    Eddingpharm 54

    Eisai Co., Ltd. 55

    Eli Lilly and Company 57

    Hutchison MediPharma Limited 58

    Incyte Corporation 59

    Johnson & Johnson 60

    Les Laboratoires Servier SAS 61

    Merck KGaA 62

    Novartis AG 63

    Principia Biopharma Inc. 64

    Vichem Chemie Research Ltd. 65

    Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Drug Profiles 66

    ARQ-087 - Drug Profile 66

    Product Description 66

    Mechanism Of Action 66

    R&D Progress 66

    ASP-5878 - Drug Profile 68

    Product Description 68

    Mechanism Of Action 68

    R&D Progress 68

    AV-370 - Drug Profile 69

    Product Description 69

    Mechanism Of Action 69

    R&D Progress 69

    AZD-4547 - Drug Profile 70

    Product Description 70

    Mechanism Of Action 70

    R&D Progress 70

    B-701 - Drug Profile 72

    Product Description 72

    Mechanism Of Action 72

    R&D Progress 72

    BAY-1163877 - Drug Profile 73

    Product Description 73

    Mechanism Of Action 73

    R&D Progress 73

    BMS-986036 - Drug Profile 74

    Product Description 74

    Mechanism Of Action 74

    R&D Progress 74

    CPL-043 - Drug Profile 75

    Product Description 75

    Mechanism Of Action 75

    R&D Progress 75

    Debio-1347 - Drug Profile 76

    Product Description 76

    Mechanism Of Action 76

    R&D Progress 76

    E-7090 - Drug Profile 78

    Product Description 78

    Mechanism Of Action 78

    R&D Progress 78

    EDP-317 - Drug Profile 79

    Product Description 79

    Mechanism Of Action 79

    R&D Progress 79

    ENMD-2076 - Drug Profile 80

    Product Description 80

    Mechanism Of Action 80

    R&D Progress 80

    erdafitinib - Drug Profile 85

    Product Description 85

    Mechanism Of Action 85

    R&D Progress 85

    HMPL-453 - Drug Profile 87

    Product Description 87

    Mechanism Of Action 87

    R&D Progress 87

    INCB-54828 - Drug Profile 88

    Product Description 88

    Mechanism Of Action 88

    R&D Progress 88

    infigratinib - Drug Profile 89

    Product Description 89

    Mechanism Of Action 89

    R&D Progress 89

    lenvatinib mesylate - Drug Profile 91

    Product Description 91

    Mechanism Of Action 91

    R&D Progress 91

    lucitanib - Drug Profile 104

    Product Description 104

    Mechanism Of Action 104

    R&D Progress 104

    LY-2874455 - Drug Profile 107

    Product Description 107

    Mechanism Of Action 107

    R&D Progress 107

    masitinib - Drug Profile 108

    Product Description 108

    Mechanism Of Action 108

    R&D Progress 108

    nintedanib - Drug Profile 121

    Product Description 121

    Mechanism Of Action 121

    R&D Progress 121

    pazopanib hydrochloride - Drug Profile 130

    Product Description 130

    Mechanism Of Action 130

    R&D Progress 130

    pazopanib hydrochloride + pembrolizumab - Drug Profile 137

    Product Description 137

    Mechanism Of Action 137

    R&D Progress 137

    PRN-1371 - Drug Profile 138

    Product Description 138

    Mechanism Of Action 138

    R&D Progress 138

    Recombinant Peptide to Antagonize FGFR3 for Achondroplasia - Drug Profile 139

    Product Description 139

    Mechanism Of Action 139

    R&D Progress 139

    Recombinant Protein to Agonize FGFR for Type 2 Diabetes - Drug Profile 140

    Product Description 140

    Mechanism Of Action 140

    R&D Progress 140

    Recombinant Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile 141

    Product Description 141

    Mechanism Of Action 141

    R&D Progress 141

    S-49076 - Drug Profile 142

    Product Description 142

    Mechanism Of Action 142

    R&D Progress 142

    Small Molecules to Antagonize Pan FGFR for Oncology - Drug Profile 143

    Product Description 143

    Mechanism Of Action 143

    R&D Progress 143

    sprifermin - Drug Profile 144

    Product Description 144

    Mechanism Of Action 144

    R&D Progress 144

    Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Dormant Projects 146

    Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Discontinued Products 151

    Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Featured News & Press Releases 153

    Oct 26, 2016: Eisais LENVIMA (lenvatinib) Nominated for Galien Foundations Best Pharmaceutical Product 153

    Oct 24, 2016: Efficacy of Ofev (nintedanib) Reinforced in Range of Patients with IPF in New Analyses Presented at CHEST 153

    Oct 12, 2016: Preliminary Phase Ib Clinical Study Results for Lenvatinib in Combination with Pembrolizumab in Selected Solid Tumors Presented at ESMO 2016 154

    Oct 09, 2016: ESMO 2016: Lenvatinib Shows Promising Activity in Patients with RET-Positive Adenocarcinoma of the Lung 156

    Oct 09, 2016: People with an Advanced Form of Thyroid Cancer Now Able to Benefit From Lenvima (lenvatinib) in Scotland 157

    Oct 09, 2016: Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO 159

    Oct 08, 2016: Phase I study of novel anti-cancer drug uses tumor mRNA expression to identify responders 159

    Oct 03, 2016: AB Science has been invited at four international meetings to present new preclinical data showing neuroprotective effect of masitinib in amyotrophic lateral sclerosis (ALS) 160

    Sep 30, 2016: Eisai To Initiate Phase III Clinical Study Of Anticancer Agent Lenvatinib As Potential First-Line Therapy For Advanced Renal Cell Carcinoma 162

    Sep 29, 2016: Eisai To Present Latest Data On Lenvatinib At ESMO Congress 2016 163

    Sep 29, 2016: AB Science Announces the Filing of Masitinib in the Treatment of Amyotrophic Lateral Sclerosis (ALS) to the European Medicines Agency 164

    Sep 28, 2016: Bayer presents New Data on BAY 1163877 at ESMO 2016 Congress 165

    Sep 21, 2016: Eisai to Present Updates on Lenvatinib in Two Types of Thyroid Cancer at 86th Annual Meeting of the American Thyroid Association 165

    Sep 15, 2016: Eisai Receives License For New Indication For Anticancer Agent Kisplyx (Lenvatinib Mesylate) For Treatment Of Advanced Renal Cell Carcinoma 166

    Sep 15, 2016: ArQule Announces Publication of Manuscript Highlighting Preclinical Activity of FGFR Inhibitor, ARQ 087, in Peer Reviewed Journal 167

    Appendix 168

    Methodology 168

    Coverage 168

    Secondary Research 168

    Primary Research 168

    Expert Panel Validation 168

    Contact Us 168

    Disclaimer 169

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

32495 | GMDHC0670TDB

Number of Pages

169

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H1 2017
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H1 2017Summar...
13 Jun 2017 by Global Markets Direct USD $2,975 (normally
USD $3,500)
More Info
SAVE 15% today! Fibroblast Activation Protein (FAP or Seprase) Inhibitors -Pipeline Insights, 2017
DelveInsight’s, “Fibroblast Activation Protein (FAP or Seprase) Inhibitors-Pipeline Insights, 2017”,...
30 May 2017 by Delve Insight USD $1,063 (normally
USD $1,251)
More Info
SAVE 15% today! Fibroblast Growth Factor (FGF) Inhibitors -Pipeline Insights, 2017
DelveInsight’s, “Fibroblast Growth Factor (FGF) Inhibitors-Pipeline Insights, 2017”, report provides...
30 May 2017 by Delve Insight USD $1,063 (normally
USD $1,251)
More Info
SAVE 15% today! Fibroblast Growth Factor 1 (FGF-1) Inhibitors -Pipeline Insights, 2017
DelveInsight’s, “Fibroblast Growth Factor 1 (FGF-1) Inhibitors-Pipeline Insights, 2017”, report prov...
30 May 2017 by Delve Insight USD $1,063 (normally
USD $1,251)
More Info
SAVE 15% today! Fibroblast Growth Factor Receptor (FGFR) Agonists -Pipeline Insights, 2017
DelveInsight’s, “Fibroblast Growth Factor Receptor (FGFR) Agonists-Pipeline Insights, 2017”, report ...
30 May 2017 by Delve Insight USD $1,063 (normally
USD $1,251)
More Info
SAVE 15% today! Fibroblast Growth Factor Receptor (FGFR) Inhibitors -Pipeline Insights, 2017
DelveInsight’s, “Fibroblast Growth Factor Receptor (FGFR) Inhibitors-Pipeline Insights, 2017”, repor...
30 May 2017 by Delve Insight USD $1,063 (normally
USD $1,251)
More Info
SAVE 15% today! Fibroblast Growth Factor Receptor 1 (FGFR1) Agonists -Pipeline Insights, 2017
DelveInsight’s, “Fibroblast Growth Factor Receptor 1 (FGFR1) Agonists-Pipeline Insights, 2017”, repo...
30 May 2017 by Delve Insight USD $1,063 (normally
USD $1,251)
More Info
SAVE 15% today! Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Review, H2 2016
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine ...
16 Nov 2016 by Global Markets Direct USD $2,975 (normally
USD $3,500)
More Info
SAVE 15% today! Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Pipeline Review, H2 2016
Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 o...
16 Nov 2016 by Global Markets Direct USD $2,975 (normally
USD $3,500)
More Info
SAVE 15% today! Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Pipeline Review, H2 2016
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF...
09 Nov 2016 by Global Markets Direct USD $2,975 (normally
USD $3,500)
More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Pipeline Review, H2 2016 [Published by Global Markets Direct] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...